Q4 2024 Iovance Biotherapeutics Inc Earnings Call Transcript

Feb 27, 2025 / 09:30 PM GMT

Transcript 10-K8-K

Key Points

Positve

Iovance Biotherapeutics Inc (IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million.
The company has a robust manufacturing network with a capacity to supply more than 1,200 patients annually, and plans to expand this capacity further.
Iovance Biotherapeutics Inc (IOVA) has favorable medical coverage policies, with approximately 75% of AntagB patients covered by private payers and broad reimbursement access.
The company is on track with its XS launch expansion plans, aiming for three new approvals and early access in several new markets.
Iovance Biotherapeutics Inc (IOVA) has a strong intellectual property portfolio with over 250 granted or allowed patents, providing exclusivity through at least 2042.

Negative

The company reported a net loss of $372.2 million for the full year 2024, although this was an improvement from the previous year.
There are challenges in scaling up ATCs, with only 13% of them having infused more than 10 patients, indicating room for growth but also current limitations.
The company faces competition from potential new entrants in the market, which could impact their market share.
Manufacturing and operational costs remain high, with cost of sales for the full year 2024 at $124 million.
There is uncertainty regarding the timing and success of future regulatory approvals and market expansions, which could affect revenue projections.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IOVA.OQ - Iovance Biotherapeutics Inc
Q4 2024 Iovance Biotherapeutics Inc Earnings Call
Feb 27, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good-day, and thank you for standing by.

Welcome to the Iovan Biotherapeutics, 4th quarter and full year 2024 financial results conference call.

At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.

To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message, advising your hand is raised.

To withdraw your question, please press 11 again.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Sarah Pellegrino, SDP of Investor relations and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.